Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952966 | 0.88 | SLC5A2 (0.38) | SLC5A2MEN1PABPC1KMT2AADORA3 | |
| SCHEMBL6953129 | 0.85 | MEN1 (0.36) | SLC5A2MEN1PABPC1KMT2A | |
| SCHEMBL6952141 | 0.84 | SLC5A2 (0.37) | SLC5A2MEN1PABPC1KMT2AADORA3 | |
| SCHEMBL6952369 | 0.81 | SLC5A2 (0.42) | SLC5A2MEN1PABPC1KMT2A | |
| SCHEMBL6955130 | 0.80 | SLC5A2 (0.33) | SLC5A2MEN1PABPC1KMT2A | |
| SCHEMBL6950811 | 0.78 | SLC5A2 (0.44) | SLC5A2MEN1PABPC1KMT2A | |
| SCHEMBL6956786 | 0.74 | LMNA (0.42) | — | |
| SCHEMBL6948564 | 0.74 | HDAC6 (0.42) | SLC5A2MEN1PABPC1KMT2AADORA3 | |
| SCHEMBL3548084 | 0.74 | HDAC6 (0.42) | SLC5A2MEN1PABPC1KMT2AADORA3 | |
| SCHEMBL6948571 | 0.74 | HDAC6 (0.42) | SLC5A2MEN1PABPC1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994890-B1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6455507-B1 | E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO WELLCOME INC. | 2002-07-18 | — | — | US | disclosed |
| EP-0994890-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998056761-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | ZC3HAV1, BRPF3, BRD3 | SLC5A2 2049/4885MEN1 2972/4885PABPC1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.